Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visipaque Renal Safety in CKD Patients Post-EVAR
NCT03119662Phase 4Terminated
- Sponsor
- GE HealthCare
- Start
- Feb 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised, double-blind trial of iodixanol in abdominal aortic aneurysm (AAA) (2 arms), sponsored by GE HealthCare. Primary endpoint: Assessment of the Incidence of Acute Kidney Injury (AKI) Stage >=1 Per Acute Kidney Injury Network (AKIN) Serum Creatinine (SCr) Criteria. Started Feb 2018; status: terminated.
02
Drugs
iodixanol
03
Conditions
abdominal aortic aneurysm (AAA)
Beyond the preview
Go deeper on NCT03119662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119662.